Company / Revenue per Share
AVADEL PHARMACEUTICALS PLC Revenue per Share History
FY2015-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Revenue per Share
$1.78
FY2024
5-year range
$0.00 / $1.78
FY2020-FY2024
Trend
+409.6%
vs FY2023
Sector context
#95 of 154
Health Care
What the data says
Revenue per Share changed +410% YoY in FY2024, a notable deviation from the 7-year average annual change of +24%.
Based on SEC 10-K filings.
1.78 in FY2024 with a 5-year CAGR of +2.3%.
Improved from $0.00 to $1.78 over the past 2 years.
Health Care sector context is included.
Revenue per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- +2.3%
- 10-Year CAGR
- -
Sector benchmark
#95 of 154 in Health CareTop 62% of 154This company $1.78 Sector average $15.09
▼
-88.2% below sector average
Key checks
Key Insights
- In FY2024, revenue per share increased 409.6% year-over-year.
- Ranks #95 out of 154 companies in the Health Care sector.
- Peak revenue per share was recorded in FY2017.
- Lowest revenue per share in the period was in FY2022.
Company context
Key Data Points
- Altman Z-Score 0.94 (distress zone, below 1.8 threshold)
- Negative profit margin: -28.9%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Revenue per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $1.78 | +409.6% |
| FY2023 | $0.35 | - |
| FY2022 | $0.00 | - |
| FY2021 | $0.00 | -100.0% |
| FY2020 | $0.41 | -74.3% |
| FY2019 | $1.58 | -42.8% |
| FY2018 | $2.77 | -33.3% |
| FY2017 | $4.15 | +13.9% |
| FY2016 | $3.64 | -8.2% |
| FY2015 | $3.97 | +859.2% |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026